These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 1855435)

  • 41. The effect of continuous subcutaneous insulin infusion on insulin binding to erythrocytes in diabetes mellitus.
    Ng FM; Babacan E; Cohen M; Zimmet PZ
    Diabetes Res Clin Pract; 1987; 3(1):31-7. PubMed ID: 3545728
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Insulin action on glucose and branched-chain amino acid metabolism in cancer cachexia: differential effects of insulin.
    Pisters PW; Cersosimo E; Rogatko A; Brennan MF
    Surgery; 1992 Mar; 111(3):301-10. PubMed ID: 1542855
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Substitution of night-time continuous subcutaneous insulin infusion therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory hormonal responses and warning symptoms of hypoglycaemia in IDDM.
    Kanc K; Janssen MM; Keulen ET; Jacobs MA; Popp-Snijders C; Snoek FJ; Heine RJ
    Diabetologia; 1998 Mar; 41(3):322-9. PubMed ID: 9541173
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Accuracy assessment of online glucose monitoring by a subcutaneous enzymatic glucose sensor during exercise in patients with type 1 diabetes treated by continuous subcutaneous insulin infusion.
    Radermecker RP; Fayolle C; Brun JF; Bringer J; Renard E
    Diabetes Metab; 2013 May; 39(3):258-62. PubMed ID: 23522730
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The influence of insulin antibodies on metabolic deterioration after interruption of continuous subcutaneous insulin infusion.
    Montaña E; Fernández-Castañer M; Rosel P; Gómez JM; Vinzia C; Soler J
    Diabete Metab; 1990; 16(3):220-5. PubMed ID: 2210017
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rarity of a marked "dawn phenomenon" in diabetic subjects treated by continuous subcutaneous insulin infusion.
    Bending JJ; Pickup JC; Collins AC; Keen H
    Diabetes Care; 1985; 8(1):28-33. PubMed ID: 3971844
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Improvement of β-cell function after achievement of optimal glycaemic control via long-term continuous subcutaneous insulin infusion therapy in non-newly diagnosed type 2 diabetic patients with suboptimal glycaemic control.
    Choi SB; Lee JH; Lee JH; Kim S; Han SD; Kim IH; Noh YH
    Diabetes Metab Res Rev; 2013 Sep; 29(6):473-82. PubMed ID: 23592489
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Calculating the insulin to carbohydrate ratio using the hyperinsulinaemic-euglycaemic clamp-a novel use for a proven technique.
    Bevier WC; Zisser H; Palerm CC; Finan DA; Seborg DE; Doyle FJ; Wollitzer AO; Jovanovic L
    Diabetes Metab Res Rev; 2007 Sep; 23(6):472-8. PubMed ID: 17315240
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hypoglycemia and counterregulation in insulin-dependent diabetic patients: a comparison of continuous subcutaneous insulin infusion and conventional insulin injection therapy.
    Ng Tang Fui S; Pickup JC; Bending JJ; Collins AC; Keen H; Dalton N
    Diabetes Care; 1986; 9(3):221-7. PubMed ID: 3525052
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects.
    Orskov L; Nyholm B; Yde Hove K; Gravholt CH; Møller N; Schmitz O
    Diabet Med; 1999 Oct; 16(10):867-74. PubMed ID: 10547215
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Free insulin levels and metabolic effects of meal-time bolus and square-wave intraperitoneal insulin infusion in insulin-dependent diabetic patients.
    Jimenez JT; Walford S; Home PD; Hanning I; Alberti KG
    Diabetologia; 1985 Oct; 28(10):728-33. PubMed ID: 3905470
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Changes in basal insulin infusion rates with subcutaneous insulin infusion: time until a change in metabolic effect is induced in patients with type 1 diabetes.
    Heinemann L; Nosek L; Kapitza C; Schweitzer MA; Krinelke L
    Diabetes Care; 2009 Aug; 32(8):1437-9. PubMed ID: 19487635
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A 2-way cross-over, open-labeled trial to compare efficacy and safety of insulin Aspart and Novolin R delivered with CSII in 21 Chinese diabetic patients.
    Bi YF; Zhao LB; Li XY; Wang WQ; Sun SY; Chen YH; Hong J; Su TW; Liu JM; Ning G
    Chin Med J (Engl); 2007 Oct; 120(19):1700-3. PubMed ID: 17935674
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
    Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
    Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Continuous subcutaneous insulin infusion (Mill-Hill Infuser) versus multiple injections (Medi-Jector) in the treatment of insulin-dependent diabetes mellitus and the effect of metabolic control on microangiopathy.
    Chiasson JL; Ducros F; Poliquin-Hamet M; Lopez D; Lecavalier L; Hamet P
    Diabetes Care; 1984; 7(4):331-7. PubMed ID: 6381006
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.
    Torres I; Ortego J; Valencia I; García-Palacios MV; Aguilar-Diosdado M
    Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):378-85. PubMed ID: 19629931
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improved in vivo insulin effect during continuous subcutaneous insulin infusion in patients with IDDM.
    Beck-Nielsen H; Richelsen B; Hasling C; Nielsen OH; Heding L; Sørensen NS
    Diabetes; 1984 Sep; 33(9):832-7. PubMed ID: 6381179
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Plasma lipid fatty acids and platelet function during continuous subcutaneous insulin infusion in type I diabetes.
    Monnier LH; Rodier M; Gancel A; Crastes de Paulet P; Colette C; Piperno M; Crastes de Paulet J
    Diabete Metab; 1987 Jun; 13(3):210-6. PubMed ID: 3301444
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effects of HDV-insulin on carbohydrate metabolism in Type 1 diabetic patients.
    Davis SN; Geho B; Tate D; Galassetti P; Lau J; Granner D; Mann S
    J Diabetes Complications; 2001; 15(5):227-33. PubMed ID: 11522495
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Insulin absorption is faster when keeping the infusion site in use for three days during continuous subcutaneous insulin infusion.
    Liu D; Moberg E; Wredling R; Lins PE; Adamson U
    Diabetes Res Clin Pract; 1991 Apr; 12(1):19-24. PubMed ID: 1855437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.